Status:
COMPLETED
Protective Effect of EPA on Cardiovascular Events
Lead Sponsor:
Kobe University
Collaborating Sponsors:
Mochida Pharmaceutical Company, Ltd.
Conditions:
Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
Eligibility:
All Genders
40-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alo...
Detailed Description
Epidemiological studies from many countries including Finland, Italy, Japan, and The Netherlands have suggested that an increased intake of dietary fish or fish oil rich in the long-chain polyunsatura...
Eligibility Criteria
Inclusion
- Eligible participants had a total cholesterol level of ≧250mg/dL(6.5m mol/L) at baseline.
- Hyperlipidemic patients with serum total cholesterol of 250mg/dL or more. (Measurement of serum total cholesterol)
- Serum total cholesterol should be measured twice at interval of 2-4weeks. A single measurement is acceptable if the cholesterol is measured by blood collection at fasting under strict compliance with dietary advice after withdrawal of the antihyperlipemic drug.
- (Wash Out) The wash out period of 4weeks (8 weeks for probucol) is necessary in patients under treatment with antihyperlipemic drug. However, if treatment with the antihyperlipemic drug was started within 6 months of the initiation of the study, the patient can participate in the study without the washout period.
Exclusion
- Acute myocardial infarction occurring within last 6 months
- Unstable angina pectoris
- A history or complication of serious heart disease(severe arrhythmia, heart failure, cardiac myopathy, valvular disease, congenital disease, etc.)
- Receiving cardiovascular reconstruction within last 6 months
- Cerebrovascular disorders occurring within last 6 months
- Complication of serious hepatic disease or renal disease
- Malignant tumor
- Uncontrollable diabetes
- Hyperlipidemia arising from the following disease: Nephrotic syndrome, hypothyroidism, Cushing's syndrome, secondary hyperlipidemia due to other disease
- Hyperlipidemia due to some drugs such as steroid hormone
- Hemorrhage(hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage, etc.)
- Hemorrhagic diathesis
- Hypersensitivity to the study drug formulation
- Patients intending to undergo surgery
- Patients judged to be inappropriate by the physician in charge
Key Trial Info
Start Date :
November 1 1996
Trial Type :
INTERVENTIONAL
End Date :
November 1 2004
Estimated Enrollment :
18000 Patients enrolled
Trial Details
Trial ID
NCT00231738
Start Date
November 1 1996
End Date
November 1 2004
Last Update
November 20 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kobe University Graduate School of Medicine Cardiovascular and Respiratory Medicine Division, Department of Internal Medicine
Kobe, Hyōgo, Japan, 650-0017